Inhibrx Biosciences (INBX) Debt Ratio (2023 - 2026)

Inhibrx Biosciences (INBX) posted quarterly Debt Ratio of 0.69 for Q4 2025, up 21.94% quarter-over-quarter from 0.56 in Q3 2025.

Analysis

Inhibrx Biosciences (INBX) Debt Ratio (2023 - 2026) Analysis & Trends

Inhibrx Biosciences (INBX) has reported Debt Ratio for 2 consecutive years, with 0.69 the latest figure, recorded in Q4 2025.

In Q4 2025, Debt Ratio changed N/A year-over-year to 0.69; the TTM figure through Dec 2025 stood at 0.69 (changed N/A YoY), while the FY2025 annual figure was 0.69, changed N/A from the prior year.
Debt Ratio climbed to 0.69 in Q4 2025 per INBX's latest filing, from 0.56 in the prior quarter.
Across five years, Debt Ratio topped out at 0.69 in Q4 2025 and bottomed at 0.41 in Q1 2025.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	0.05
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	0.05
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	0.12
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	0.47
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	0.26
10	Inhibrx Biosciences	1.91 Bn	1.91 Bn	-	1.14

Historic Data

Download Data